Keenova Therapeutics
Specialty pharma -- reorganizing post-Chapter-11 (targeting a 2026 NYSE relisting as "Keenova"), ticker deliberately left null given the transitional OTC listing
Privately held: no public share price · Ireland
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | 5-HT1B/1D receptorSmall molecule | Migraine | |
nitric oxide(INOmax) | Approved | Nitric oxideOther | Persistent Pulmonary Hypertension of the Newborn |
| Approved | Melanocortin receptors (primarily MC2R on the adrenal cortex) · Melanocortin 2 receptor (MC2R) (agonist)Peptide | Psoriatic ArthritisSystemic Lupus ErythematosusRheumatoid ArthritisMultiple SclerosisEpilepsyDermatomyositisNon-Infectious UveitisIdiopathic Inflammatory MyopathiesLupus Nephritis Multiple Sclerosis Exacerbations | |
| Approved | 5-HT1B/1D receptorSmall molecule | Migraine |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | $753M | $44M | $1.0B | $291M | report ↗ |
Mallinckrodt reported third-quarter 2025 net sales of $753.1M, up 49.0% YoY, with R&D spend of $44.3M and cash and equivalents of $1,047.9M. The company reported a net loss of $291.1M for the quarter, versus a net loss of $26.2M in the prior-year period, and adjusted EBITDA of $111.3M.
Management guided fourth-quarter 2025 Keenova net sales of $485M to $505M and adjusted EBITDA of $155M to $165M, while raising full-year Acthar Gel net sales growth guidance to 30% to 35%. The company completed its merger with Endo on July 31, 2025, initiated a XIAFLEX clinical program for hammertoe with over 30 patients recruited, and completed the spin-off of its generics and sterile injectables businesses as Par Health, with the branded therapeutics business now operating as Keenova Therapeutics.
Annual history (1 year)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $1.4B | — | $813M | $490M | report ↗ |